Acupoints, Fallopian Tube Obstruction, Laser
Conditions
Brief summary
This study aims to determine the efficacy of laser acupoint therapy on treating fallopian tube obstruction.
Detailed description
Fallopian tube obstruction is a significant health concern that affects a substantial number of women worldwide, often leading to infertility and other reproductive issues. The fallopian tubes, essential components of the female reproductive system, play a crucial role in the process of conception by facilitating the transport of ova from the ovaries to the uterus. The laser's focused light energy, when directed at specific acupoints linked to reproductive health, is hypothesized to activate the body's energy pathways or meridians, thereby facilitating healing and restoration of normal tubal function. Although acupoint therapy shows promise, laser acupoint therapy offers potential advantages over traditional acupuncture by utilizing low-level lasers, which may enhance the treatment's efficacy. Laser acupoint therapy is noninvasive and painless, making it articularly appealing for patients who have a fear of needles or are sensitive to pain.
Interventions
OTHERLaser acupoints therapy + Standard care
Patients will receive laser acupoints therapy addition to standard care.
OTHERStandard care
Patients will receive placebo laser acupoints therapy in addition to standard care.
Sponsors
Kafrelsheikh University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
20 Years to 35 Years
Healthy volunteers
No
Inclusion criteria
* Women aged 20-35 years - nulliparous. * Women diagnosed with fallopian tube obstruction. * Body mass index less than 30 kg/m2. * Consent to participate in the study. * General good health with no major co-existing medical conditions that could interfere with the treatment or outcomes. * No prior fertility treatments \[e.g., In vitro fertilization (IVF), intrauterine insemination (IUI)\] within the last 6 months. * Ability to attend all scheduled sessions and follow-up assessments.
Exclusion criteria
* Currently pregnant or breastfeeding. * History of pelvic surgery within the past year. * Presence of severe systemic diseases such as active cancer or severe cardiovascular diseases. * History of allergic reactions or adverse responses to acupuncture or laser therapies. * Currently undergoing hormonal therapy or use of hormonal contraceptives. * Current or recent history of genital tract infections, including sexually transmitted. infections, which could affect the reproductive system. * Presence of significant uterine anomalies diagnosed through imaging that could impact fertility. * Polycystic Ovary Syndrome (PCOS).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Tubal patency | 3 months post-treatment | Hysterosalpingography (HSG) will be used to assess tubal patency. It is a radiographic technique where a contrast material is injected into the uterine cavity, and X-ray images are taken to evaluate the shape of the uterus and the status of the fallopian tubes. HSG will be applied before the treatment and again three months post-treatment to evaluate changes in tubal patency HSG will be applied before treatment and after 3 months post-treatment. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Anti-Müllerian Hormone (AMH) Test | 3 months post-treatment | A blood test will be used to measure the level of Anti-Müllerian Hormone (AMH), which is an indicator of the remaining quantity of eggs and ovarian function. This test will be conducted before the treatment and at the third month of treatment to monitor any changes in ovarian reserve. |
| Quantitative Pregnancy Test | 3 months post-treatment | A blood test that will be measured the specific level of Human Chorionic Gonadotropin (hCG), which is produced during pregnancy. This test will be performed every month. |
Countries
Egypt
Contacts
CONTACTHadeer E Shalaby, MBBCH
Outcome results
None listed